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Abstract
Alzheimer's disease is a devastating illness that is
common among the nursing home population.

Treatment for

Alzheimer's disease is usually palliative and consists of
using psychotropic medications to control aggressive and
agitated behaviors exhibited by its victims.

The purpose

of this descriptive study was to identify behaviors
exhibited by Alzheimer's disease patients before and after
receiving psychotropic medications.

Johnson's Behavioral

System Model was used as the theoretical framework for
this study.

The sample

(N = 33) consisted of nursing home

residents with a diagnosis of Alzheimer's disease who were
treated with one psychotropic medication.

The researcher

used chart review to examine the behaviors exhibited by
the patients and the psychotropic medication received.
Data were gathered using the Behavioral Assessment for
Institutionalized Alzheimer's Patients. Data analysis
consisted of descriptive statistics and t, tests to measure
significant changes in behaviors.

Six categories of

measurement included memory/recall ability,
skills for daily decision making,

indicators of delirium-

periodic disordered thinking/awareness,
depression,

anxiety,

sad mood,
iii

cognitive

indicators of

and behavioral symptoms.

Findings revealed significant changes in all areas
measured.

Conclusions derived from the study were that

psychotropic medications significantly impact behaviors of
the Alzheimer's disease patient.

Recommendations include

replication of the study with a larger sample,
of the tool utilized to measure behaviors,

refinement

education of

personnel regarding behaviors exhibited by the Alzheimer's
disease patient,

and comparison of the effects of

different psychotropic medications on the behaviors of the
Alzheimer's disease patient.
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Chapter I
The Research Problem
Psychotropic medications are among the most
frequently prescribed pharmacological agents for America's
elders.

Originally designed to treat individuals with a

history of documented illness,
used appropriately.

these drugs are useful when

However, misappropriate use of

psychotropic drugs has been documented by epidemiologic
evidence in research

(Sherman,

1994) .

Alzheimer's disease is the leading cause of serious
mental illness in persons over the age of 65 years.

Yet

the most significant causes of cognitive impairment in
Alzheimer's disease patients are not necessarily disease
related but may be side effects of sedative/hypnotics and
long-acting benzodiazepines

(Sherman,

1994). Although

psychotropic medications are indicated for mental illness
in persons with Alzheimer's disease,

these drugs are being

used to control behavioral problems without adequate
examination of the long-term cognitive effects
Keene,

1997; Yeager,

Farnett,

& Ruzicka,

1995).

(McShane &

Alzhei me r' s disease patients have more cognition,
memory,

and orientation problems as well as a generally

more rapid mental decline with the use of psychotropic
medications

(McShane & Keene,

1997). Nevertheless

psychotropic drugs have been used to control disruptive
behavior and sleeplessness and, therefore,
known as chemical restraints

(Castle,

have become

1999) . These drugs

were originally designed to treat individuals with a
history of documented mental illness and were not intended
to treat individuals with symptoms of dementia

(Sherman,

1994).
Conversely,

the increased sensitivity of the elderly

to various drugs has been well established
Keene,

1997).

(McShane &

Given the fact that half-life and clearance

of many drugs may be altered in elders,

routine use of

psychotropic drugs among demented elders is questionable
at best.

These drugs not only alter behaviors but increase

the risk for serious complications related to falls and
hip fractures.

Nurse practitioners in primary care and

long-term care settings are often responsible for making
decisions about instituting,

altering,

or discontinuing

use of psychotropic drugs in clients with Alzheimer's
disease. An empirical basis for making such decisions is
needed.

Therefore,

the focus of this study was to evaluate
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the behaviors of institutionalized Alzheimer's disease
patients before and after the initiation of psychotropic
medications.

Establishment of the Problem
Dementia affects 5% of persons over the age of 65
years and 20% of those over 80 years of age. The incidence
of dementia is expected to increase as the population
ages. Alzheimer's disease has been reported as the most
common form of dementia and accounts for 70% of all
nursing home admissions

(Yeager et al.,

1995) . Alzheimer's

disease follows a specific pattern of cognitive losses and
behavioral disturbances.

The impact of Alzheimer's disease

management has dramatic physical,

psychological,

and

financial consequences for patients and caregivers
(Corcoran & Gitlin,

1992). Agitated behaviors associated

with Alzheimer's disease include aggression,

irritability,

and psychotic symptoms,

including hallucinations and

delusions.

there is a progressive,

In addition,

irreversible loss of memory,

deterioration of intellectual

capacity and disorientation,

and the inability to perform

activities of daily living,
bathing,

such as dressing self,

and personal hygiene

(Sloan,

1998).

Behavioral manifestations of dementia include
disturbance in sleep and appetite,

agitation,

psychotic

4

symptoms,

apathy,

features

(Tariot,

as well as depressive and anxious
Schneider,

& Porsteinson,

1997).

These

manifestations may persist for years and eventually may
require a long-term health care approach.

Patients are

usually placed in nursing homes when caregivers can no
longer care for them at home.

The pharmacomedical economic

cost for Alzheimer's disease has been estimated at $100
million annually

(Callaway,

1998).

There has been a 12% increase in the number of
persons over the age of 65 years since 1900.

Furthermore,

the incidence of Alzheimer's disease is found in 20% to
40% of persons over the age of 80 years.
"graying of America"

(Gambert,

1997)

impact on age-prevalent disorders;

Obviously,

the

has had a notable

therefore, Alzheimer's

disease has had a profound effect on the perception of the
public and the medical community about mental illness in
elders.

Issues,

incontinence,

such as wandering,

falls,

confusion,

and sleep disorders,

agitation,

present health

care workers and families with difficult problems to
treat.
Many long-term care residents have varying degrees of
behavioral,

social,

emotional,

and mental disorders and

receive psychotropic drug therapy.

Yet,

frequently used as

a realistic treatment for behavioral problems in the

5

Alzheimer's disease patient,

psychotropic drug therapy has

led to patients being overmedicated,
status and memory,
falls

(Sherman,

declining cognitive

and an increase in the incidence of

1994).

Falls comprise the leading cause of fatal and
nonfatal injuries in persons over 75 years of age.

L on g

term psychotropic medication use has been strongly
associated with the risk of falls in nursing homes.
Research has revealed that elderly patients receiving
psychotropic medications may be two to three times more
likely to experience a fractured hip as opposed to those
who did not receive psychotropic medications

(Sherman,

1994).
In 1996 more than 250,000 older Americans suffered
fractured hips at a cost in excess of $10 billion. More
than 90% of hip fractures are associated with falls,

and

most of these falls occur in persons over the age of 70
years.

Elderly persons who fall are 10 times more likely

to be hospitalized and eight times more likely to die as
the result of a fall.

Increased risk factors for falls in

the elderly include the use of psychotropic medications,
cognitive impairment,

and sensory deficits

(Fuller,

2000).

Institutionalized elders have increased risk of serious
complications associated with falls,

such as pneumonia.
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skin breakdown,

and deep venous thrombosis

(Yeager et al.,

1995) .
Tardive dyskinesia is a condition characterized by
involuntary facial movements,

such as tongue protrusions

and grimacing. At lest 40% of elders receiving
psychotropic medications will develop some form of tardive
dyskinesia.

Despite its persistent nature,

tardive

dyskinesia is often missed or mistaken as a normal part of
the disease process

(Sherman,

1994).

Tardive dyskinesia

may be irreversible and can interfere with eating and
swallowing,

which causes weight loss and malnutrition and

can ultimately lead to death

(Yeager et al.,

1995).

Although tardive dyskinesia is persistent in nature,
can be mistaken for worsening of the disease process.

it
This

reaction frequently leads to an increase in the
psychotropic medication dose being prescribed.

Significance to Nursing
The current researcher sought to describe the
behaviors of the Alzheimer's disease patients before and
after the institution of psychotropic medications.
Findings from this study may contribute to nursing
research,

theory,

practice,

Nursing research.

and education.

This study contributed to the body

of nursing research by providing new insights into
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understanding the behaviors of the Alzheimer's disease
patient through documentation and co mparison. Conduction
of the study was important in identifying behavioral
symptoms of Alzheimer's disease patients and the
relationship between those symptoms and the medications
used to control them.

Data from this study provided

relevant information for future health care professionals
caring for Alzheimer's disease patients.

Increasing

awareness of the type of medications used underscores the
importance of issues such as safety and improving quality
of life for those with Alzheimer's disease.

Finally,

this

research serves as a springboard from which to develop
more studies focusing on the behaviors of the Alzheimer's
disease patient and the medications used to treat them.
Nursing theory.

This study served to advance

Johnson's Behavioral System M o d e l .as an appropriate basis
for describing the behaviors of the Alzheimer's disease
patient.

Johnson's concepts of behavioral systems,

equilibrium,

stressors,

and tensions are particularly

relevant to the behavior of the Alzheimer's disease
patient receiving psychotropic medication therapy.
Nursing practice.

Findings from this study may be of

significance to nurses and nurse practitioners charged
with caring for persons with Alzheimer's disease.

The
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researcher sought to enable health care workers to
understand the patient, behaviors exhibited,

and the

medications used in treatment of the behaviors.

Patients

with Alzheimer's disease receiving psychotropic
medications require special attention due to the potential
for declining cognition, memory deterioration,

and

physical limitations and the adverse effects associated
with these variables.

The informed health care

professional has the opportunity to provide holistic care
to Alzheimer's disease patients in the long-term care
facility through increased understanding of the disease
process and the medications used to control the symptoms.
Nursing education. As the elderly population
increases and long-term care facilities become more
prevalent,

the need for long-term care professionals also

will increase.

Caregivers should be educated regarding the

unique needs of the Alzheimer's disease patient and the
medications used to treat dysfunctional behaviors.

Nursing

educational systems at both the baccalaureate and masters
levels must continue to stay on the cutting edge of
research and practice as the number of Alzheimer's disease
clients in the health care delivery system continues to
increase.

Findings from this study may contribute valuable

information to such programs.

Theoretical Framework
The theoretical framework guiding this study was
Johnson's Behavioral Systems Model

(Johnson,

1968).

Johnson's model has been used in a variety of studies that
support man as a behavioral system.

In the current study

the Alzheimer's disease patient's behavioral system was
altered by both the disease and psychotropic medications.
Johnson developed the systems framework to provide
direction for nursing theory,
research.

practice,

education,

and

The goal of Johnson's theory was to maintain and

restore balance in the patient by helping him or her
achieve an optimal functional level. The major concepts of
Johnson's model used in this study were behavioral system,
equilibrium,

tension,

and stressor

(Johnson,

A behavioral system is a patterned,
intentional way of behaving.

1968) .

continual,

and

This behavior forms an

organized functional unit that provides interaction
between the person and his or her environment.

The

patterned and repetitive ways of behaving that
characterize man can be conceptualized as interrelated and
interdependent parts that make up the whole person.

This

behavioral system is determined and controlled by
biological,

psychological,

and social factors.

Certain

conditions must be met in order for the system to grow and
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survive.

Problems manifested by disorganized or erratic

behaviors represent disorders of the behavioral system.
This conceptualization represents man as a behavioral
system and disease as a biological system disorder
(Johnson,

1968). The behavioral system of the Alzheimer's

disease patient may be based on the ability to interrupt
information and be affected by the environment.
Equilibrium is defined as a secure,
temporary,

but more or less

resting state in which the individual is in

accord with himself or herself and his or her environment.
Equilibrium is not synonymous with a state of health since
it may be found either in health or illness

(Johnson,

1968) . Factors that may alter equilibrium for the
Alzheimer's disease patient include the onset of
confusion,

loss of cognitive function,

and memory.

Medications used to treat these problems may also alter
equilibrium and lead to loss of adaptation of the
behavioral system.
Stressors refer to internal and external stimuli that
produce tension and result in a degree of stability.
Johnson

(1998)

states that stress is a process in which

there is interaction between various stimuli and the
defenses constructed against them. An unusual amount of
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energy is required for the system to reestablish
equilibrium in the aspect of stressful f o r c e s .
Tension is the state of being distended or forced and
can be perceived as a disturbance in equilibrium.
can be destructive ineffective use of energy,

Tension

hindering

adaptation and causing potential structural impairment.
The stressors of the Alzheimer's disease patient usually
occur from outside stimuli.

Inability to adequately

perform activities of daily living and memory loss provoke
stress and tension which leads to agitation and
frustration.

The patient may be placed on medication to

control behaviors that result from stressors which
ultimately produce tension.
Johnson

(1968)

outlined health as an intangible,

energetic state influenced by biological,

psychological,

and social factors. An individual attempts to achieve a
balance in this system which will lead to functional
behavior. A lack of balance in the structural or
functional systems lead to poor health.
As the Alzheimer's disease patient in equilibrium
attempts to achieve balance in the system,
exhibited affect the behavioral system.

the behaviors

The psychotropic

medications used to control the patient's behavior
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produces stressors that may alter the functional level of
the system and produce tension
In summary,

(Gardner & Garrett,

1997).

Johnson's Behavioral Systems Model was

chosen as the theoretical framework to guide this study
because the concept of behavioral system and the
subconcepts of equilibrium,

stressors,

and tension were

particularly relevant to the issue of using psychotropic
medications in elders with Alzheimer's disease.

The

current researcher sought to examine the behaviors of
Alzheimer's disease clients before and after the
implementation of psychotropic drugs in order to assess
whether such drugs indeed help to maintain and restore
balance by helping the patient achieve his or her maximum
functional level.

Assumptions
The assumptions of this study were as follows:
1. Institutionalized Alzheimer's patients exhibit
behaviors that can be measured.
2. Institutionalized Alzheimer's patients are
receiving psychotropic medications to control their
behavior.
3. Charting of behaviors and medication use is
complete.

13

4.
(Johnson,

Behavior is an ever-changing dynamic process
1968).

Statement of the Problem
The number of institutionalized persons with
Alzheimer's disease is increasing as a result of the rise
in the geriatric population.

The behaviors exhibited by

the Alzheimer's disease patient present the health care
professional with a variety of concerns.

The treatment of

behavioral symptoms of patients has been controversial.
Previous studies have shown that psychotropic medications
may give rise to a worsening in cognitive decline and
intensify adverse behaviors.

Therefore,

the problem of

this descriptive comparative research was to examine the
behaviors of the institutionalized patient with
Alzheimer's disease and to determine whether these
behaviors changed after the implementation of a
pharmacologic regimen of psychotropic drugs.

Hypothesis
One null hypothesis guided this s t u d y : There will be
no significant difference in the behaviors of
institutionalized Alzheimer's disease patients before and
after receiving psychotropic medication therapy.
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Definition of Terms
For the purposes of this study,

the following terms

were defined theoretically and operationally:
1. Behaviors : the manner in which one acts ; the
actions or reactions of individuals under specific
circumstances

(Thomas,

1993).

Operationally,

include conduct such as wandering,

verbal abuse,

abuse,

socially inappropriate actions,

items,

and resisting care.

2. Alzheimer's disease patients:

disturbance

(Thomas,

apathy,

physical

screaming,

hoarding

persons with

progressive irreversible loss of memory,
intellectual functions,

behaviors

speech,

deterioration of
and gait

1993). Operationally,

Alzheimer's

disease patients were all males and females at least 60
years of age in the chosen institution at varying stages
of Alzheimer's disease who had received at least one
psycotropic medication.
3. Psychotropic medication therapy: medications
classified according to the Physician's Desk Reference
(AstraZeneca,

2000)

sedative/ hypnotic,
psychic function,
Operationally,
anxiolytics,

as antidepressants,

antipsychotics,

and antianxiety agents that affect

behavior,

or experience

(Thomas,

1993).

psychotropic medications classified as

antidepressants,

hypnotics,

and antipsychotic
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prescribed for the patient population in the designated
i ns ti tu t io n,

Summary
The focus of the study was to identify behaviors of
the institutionalized Alzheimer's disease patient before
and after receiving psychotropic medication therapy.

In

Chapter I the problem was introduced and the significance
to nursing was described as well as the theoretical
framework identified.

One null hypothesis guided the

researcher in assessing whether a difference in
Alzheimer's disease patients'

behaviors was appreciated.

Chapter II
Review of the Literature
In a selected review of the literature,

several

studies were found related to Alzheimer's disease patients
in nursing homes.

However,

studies specifically linking

the role of psychotropic drugs to cognitive decline in
Alzheimer's disease patients were limited.
Castle

(1999)

sought to identify resident and

facility risk factors from the use of psychotropic drugs
since the implementation of the Nursing Home Reform Act
(NHRA)

of 1987. The facility risk factors included

facility size, Medicaid admissions,

and patient census

while resident risk factors included age, agitation,
gender,

and cognitive decline.

Castle further sought to

compare the findings with resident and facility risk
factors of psychotropic drug use prior to the
implementation of the NHRA.
Castle

(1999)

defined psychotropic drugs as those

that affect psychic function,

behavior,

included the following four classes:
antidepressant, sedative/hypnotic,
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or experience and

antianxiety,

and antipsychotic.

The
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purpose of Castle's

(1999)

study was to determine the

relationships between nursing home size,
class census,

demographic area,

reimbursement

clinical type,

and

corporate setting and the use of psychotropic drugs. A
total of 268 facilities participated in the study.
facility,

depending on size,

a fixed target sample of 8,

12, or 16 residents was selected,
4,258.

for a final sample of

Two multivariate logistic regression models were

used to predict psychotropic drug administration.
were studied pre-NHRA
2,088).

In each

(n = 2,170)

and post-NHRA

(n =

The researcher used resident interviews,

interviews,

Subjects

staff

and review of the resident record,

specifically the Minimum Data Set

(MDS)

assessment tool,

to gather data. A multistage cluster sampling was used to
analyze the data.

The result was a more precise comparison

of the differences between the groups being researched.
Castle

(1999)

NHRA guidelines,

found that before the institution of

physical impairments,

increased age,

and

prior stroke were significantly less likely to be
associated with antipsychotic drug use.
cognitive impairment,

dementia,

Increased

depression,

and a history

of psychiatric problems considerably increased the use of
psychotropic drug administration.

The researcher also

found a nursing home being part of a chain of nursing
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homes was associated with a l o w e r .use of psychotropic
agents

(Castle,

1999) .

In 1993, post-NHRA increased physical and cognitive
impairments,

being female and having dementia,

depression,

and anxiety disorders increased the likelihood of
psychotropic drug administration.

Facilities with high

occupancy of Medicaid patients were 13.8 times more likely
to give antipsychotic medications,

while overall a higher

number of beds in the facility significantly decreased the
administration of antipsychotics.

Residents with anxiety

disorders were more likely to receive antianxiety
medication than other residents.

The criteria for

prescribing psychotropic medications became more rigid in
1993,

requiring more symptoms and behaviors. A major

finding was that a history of psychiatric problems was
still a significant reason for using antipsychotic
medications.
Findings from the Castle

(1999)

study support the

current research in view of the fact that the Nursing Home
Reform Act of 1987 did initiate more stringent guidelines
for psychotropic medication use in the nursing home
setting.

Despite the NHRA, psychotropic medications

continue to be used to control behaviors of Alzheimer's
disease patients regardless of nursing home size or
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reimbursement status.

Therefore,

it is important for

health care providers in long-term care settings continue
to empirically assess whether such interventions
significantly impact residents'

behaviors,

safety,

and

well-being.
Berg and Dellagega

(1996)

sought to explore the

immediate and long-term consequences of psychoactive drug
use on specific measures of intelligence and memory as
indicators of overall cognitive ability.

The researchers

believed that negative effects occurred with use of the
long-term use of psychoactive drugs among the elderly,
both in the community and in the nursing homes,
specifically in cognitive functional ability.

The World

Health Organization classification system was used to
identify psychotropic medications as neuroleptic,
antidepressants,

anxiolytics,

and sedative/hypnotic.

This longitudinal study included subjects taken from
gerontological and geriatric populations.

The studies were

based on random samples drawn from the population in
Gotenberg,

Sweden. An original sample of 743 persons aged

70 years was used.

The continuing sample was followed up

at three time periods : aged 70,

75, and 79 years.

Investigative procedures consisted of a two-part
interview at each age period.

The interview was conducted
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by a registered nurse who administered a battery of 150
questions on health,
care givers,

social networks,

and medications.

the use of health

Instrumentation included

tests on mental ability and memory and intelligence.
memory test included the following:
verbal ability,

The

synonyms measuring

block design measuring spatial ability,

identical forms measuring perception,
picture recognition.

and memory measuring

Intelligence was evaluated by fluid

and crystallized knowledge and attention.
Two different approaches were used for data analysis.
One was cross-sectional using the total groups at age 70,
75, and 79 years,

and the other was a repeated measures

longitudinal design using only those still alive at age 79
years and with valid scores at all three measurement
points.

The results of this analysis revealed that by age

75 the use of psychotropic medications increased to 39%
from 29% at age 70. By age 79 the overall rate dropped to
36%.
Chi-square analysis revealed significant differences
in the use of psychotropic medications based on gender at
all three points of measurement.

Women received more

psychotropic medications than men.
To examine the relationship between the use of
psychotropic medications and cognition,

a separate
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cross-sectional analysis of performance scores was used,
student's ;t tests were used to compare cognitive function
between users and nonusers.

Berg and Dellagega

(1996)

determined that elders at age 70 years who used
psychotropic medications had significantly lower mean
scores on the tests of verbal ability,

spatial ability,

and picture recognition and at age 75 lower scores on
verbal ability,

perception speed,

7 9-year-old group,

and digit span.

In the

all cognitive tests regressed backward

and picture recognition was significantly lower for those
subjects using psychotropic medications.
Berg and Dellagega

(1996)

concluded that as subjects

aged they received increasing numbers of psychotropic
medications.

The highest rate of use was at age 75 years,

and women received significantly more psychotropics than
men.

Berg and Dellagega

(1996)

also found a marked t rend

toward stable functioning in subjects until these
medications were introduced at which point a drop in
cognition occurred.

However,

there was no indication that

psychotropic medications improved cognitive function for
any of the subjects at any time during the study.
study is germane to the current study in that the
Alzheimer's disease patient's cognitive loss is

This
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inevitable;

however,

the rate of decline may depend on

many factors including psychotropic medication u s e .
McShane and Keene

(1997)

sought to analyze the

relationship between neuroleptic drugs and cognitive
decline in dementia.

The researchers also investigated the

absence or presence of Lewy bodies in brain tissue
postmortem of the cognitively impaired patient receiving
neuroleptics.

Cross-sectional surveys have shown that

demented patients receiving neuroleptics have more
cognition problems than those who do not ; however,
neuroleptics are prescribed more often for behavioral
problems.

Side effects of neuroleptics include the

worsening of behavioral disturbance of patients with
dementia,

increased falls,

and fractures.

The hypothesis proposed by McShane and Keene

(1997)

that neuroleptics contribute to cognitive decline in
people with dementia and decline in cognitive function is
more rapid in patients treated with psychotropic
medications who have cortical Lewy bodies postmortem.
Cognitive decline was defined as increased physical
aggression,

disturbed diurnal rhythms,

and hallucinations.

persecutory ideas,

Neuroleptic drugs were those drugs

used to treat behavioral complications of dementia and
included thioridazine,

promazine,

haloperidol,

and
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chlo rpr omazine . Lewy body refers to increased
neuropathological substances typical in brain tissue of
Alzheimer's disease patients.
McShane and Keene's

(1997)

2-year longitudinal study

consisted of interviews every 4 months,

with autopsy

performed on those who died during the study.

The

dependent variable for the study was the rate of cognitive
decline.
dementia,

The independent variables were sex,
and cognitive score at study entry.

duration of
Seventy-one

subjects with dementia were recruited through general
practitioners and psychiatric nurses. Most subjects had a
diagnosis of Alzheimer's disease at autopsy.
at entry was 72 years,

The mean age

and 37 of the subjects were men.

The age of onset of dementia was less than 65 years in 11
patients,

and the mean duration of dementia was 5.7 years.

McShane and Keen
Examination

(MMSE)

(1997)

utilized the Minimental State

to measure cognitive function scores. A

multiple regression analysis was performed on the
subjects'

scores on the MMSE. Age,

sex,

duration of

dementia,

and cognitive score at study entry were entered.

Neuroleptic use and mean scores over six interviews for
hallucinations,

persecutory ideas, physical aggression,

and disturbance of diurnal rhythms were entered stepwise.
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A second analysis consisted of autopsy of 42 patients
indicating the presence or absence of cortical Lewy
bodies.

Cortical Lewy body pathology did not make an

independent predictor of cognitive decline.
The decline in the mean score for the expanded
examination in the patients who took neuroleptics was
twice those patients who did not take neuroleptics. An
increased rate of decline was also associated with
aggression,
ideas,

disturbance of diurnal rhythm,

and hallucinations.

persecutory

There was no correlation

between the rate of cognitive decline and the dose of
neuroleptic drug therapy.
A third analysis was performed to determine a
temporal relationship between the use of neuroleptics on
20 experimental subjects who had taken neuroleptics for at
least 4 months.

The decline in the mean score for the

expanded examination in the patients who had taken
neuroleptics was twice that of patients who did not take
neuroleptics.
McShane and Keene

(1997)

determined that the use of

neuroleptics causes and increases in the rate of cognitive
decline.

This association was dependent on the degree of

dementia and behavioral symptoms for which the neuroleptic
drug might have been used. The findings also revealed that
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the point when patients started treatment coincided with
an increase in the rate of cognitive decline.

The

researchers also revealed that neuroleptics used to treat
behavioral complications of dementia might worsen already
poor cognitive abilities.

The McShane and Keene

(1997)

study is relevant to the current research because
identification of the relationship between neuroleptic
medications and cognitive decline provides more scientific
information about the progression of Alzheimer's disease
and its associated behaviors.
Jacobson and Winograd

(1994)

sought to analyze the

differing perspectives among physicians,

nursing staff,

and patients about psychoactive substance use in the long
term care setting.

The researchers noted that nighttime

disorders including both i n s o m n i a .and behavior problems
had a reported incidence of 45% to 64% among
institutionalized elders.

Psychotropic medications were

used to manage these symptoms with a reported frequency of
53% to 65%. The researchers have questioned the
effectiveness,

appropriateness,

and risk/benefit of these

medications.
The psychotropic medications identified by Jacobson
and Winograd

(1994) were antipsychotics,

antidepressants,

and sedative/hypnotic.

anxiolytics,
The antipsychotic
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drugs used were haloperidol,

thioridazine,

and

trifluperazi ne. The anxiolytics included only Ativan while
the antidepressants included amitriptyline,
nortriptyline,

and trazadone.

Under the sedative/hypnotic

category were chloral hydrate,
flurazepam,

temazepam,

diphenhydramine,

and triazolam.

Jacobson and Winograd

(1994)

behavioral symptoms as agitation,
combativeness,

despramine,

wandering,

defined nighttime
restlessness,

and yelling.

Insomnia was

operationally defined as frequent awakenings,
sleep induction,

increased

and short sleep duration.

Research subjects included 58 residents in a skilled
nursing facility.

Of the 58 residents,

no psychotropic medications,

38 were receiving

5 had pro re nata

(PRN)

orders for psychotropic medications but were not receiving
any and 15

(26%) were receiving psychotropic medications

on a regular basis.

Consent was obtained from 14 of the 15

residents receiving psychotropic medications.

Three

residents were receiving psychotropic drugs on a PRN basis
at least five to six times a week.and were included in the
study.
data,

To determine which patients could provide reliable
the Folstein's MiniMental Status Examination

was used.

Of the residents who met other inclusion

(MMSE)
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criteria,

only 6 could complete the interview with MMSE

scores > 15.
Data were collected from the three following groups
of subjects:

(a) the patients themselves,

of the nursing staff,
physicians.

and

(b) 14 members

(c) the patients'

personal

Instrumentation involved the use of a

questionnaire interview.

The interview addressed four

domains related to nighttime disorders : (a) description,
(b) presumed etiology,
nighttime disorder,

(c) management,

and

(d) impact of

including side effects of medications.

The Description domain addressed the presence of insomnia
and nighttime behavior problems.

The Etiology domain

addressed the presumed source of the problem.

The

Management domain investigated the perceived efficacy of
the medications and the presence of alternate coping
strategies.

The Impact domain explored physical,

psychological,

and social effects of the disorder and the

medication.
The nurse's interview included only those domains
appropriate to their interactions with the patients.
patients responded to objective verifiable questions,
their responses were included in the study.

The

physician's interview consisted of fewer questions to
maximize participation;

however,

the physician

The
and
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questionnaire was similar enough to the patients and staff
to ensure valid comparison.
In comparing the responses of the three groups,

the

researchers noted differences when two of the groups
disagreed on the presence of a condition or a problem.

To

calculate the percentage of different responses for each
category,

the number of the responses was divided by the

two groups which had disagreed

(i.e.. Group 1, yes; Group

2, no; and Group 1, no/Group 2, yes) by the total number
of responses.
Jacobson and Winograd
of disagreements,
staff,

(1994)

found a high frequency

ranging from 47% to 63% among patients,

and physicians.

The respondents differed in

identifying the presence of nighttime disorders and in
assessing the efficacy and impact of psychotropic
medications on the patient's daily life.

Patients and

nursing staff had differing opinions 67% of the time.
nurses reported physical problems,
and frequent urination,
often as the patients.

such as pain,

The

dyspnea,

as the cause for insomnia twice as
The nurses and patients differed

33% of the time regarding medication efficacy.

In managing

their nighttime disorders the patients reported coping
methods,

such as relaxing,

members,

and prayer.

reading,

remembering family

The nursing staff did not recognize
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any of these coping methods.
psychological effects,

On questions addressing

including fatigue,

patients and

nurses disagreed 50% of the time. The patients denied
confusion while the nurses reported that confusion
occurred frequently.
The patients and the physicians disagreed on the
effectiveness of the medication 67% of the time,

with the

physicians believing the medication was effective three
times more often than the patients. While the physician
believed there were few adverse effects,

four out of six

patients felt there were adverse effects from psychotropic
medication.

The physicians believed that 10 out of 14

patients responded well to the medication and that 70% of
these patients continued to experience significant
nighttime disturbances according to the medical record.
The physicians and the nursing staff disagreed about
the presence of insomnia 43% of the time.

The nurses

thought the disorder existed twice as often as the
physicians.

They also disagreed on the effectiveness of

the medication 50% of the time, with the physicians
stating that the medication was effective more often.

The

two groups disagreed 7 9% of the time on the impact of the
medications on the patient's daily life. The nurses
identified problems for 11 out of 14 patients,

while the
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physicians reported none.

Differences in the responses

regarding the medications'

efficacy and impact raised

questions of appropriateness of psychotropic drug use
among the elders.

The nursing staff believed the

medication was effective for only 64% of the patients.
Yet,

even for these patients,

the nursing staff records

indicated that they continued to experience nighttime
disorders.
This study had two major limitations.
and Winograd
agitation,

(1994)

First,

Jacobson

did not operationally define

restlessness,

and anxiety.

Instead,

the

conditions and disorders were described in the manner used
clinically by the staff. A second limitation was the small
number of patients who completed the interview,

since only

6 of the 14 patients could complete the interview with
some degree of reliability.
Findings from the Jacobson and Winograd
suggest that patients,

nursing staff,

(1994)

study

and physicians

perceive nighttime disorders and their management
differently and improved methods of communication and
education are needed.

Despite these findings,

nursing home

patients with nighttime disorders are often managed with
psychotropic medications.
Jacobson and Winograd

The current researcher found the

(1994)

study helpful because it
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increased awareness of the differing perceptions among
patients,

staff,

and physicians regarding the use of

psychotropic medications and control of behavioral
symptoms.

The nursing staff indicated increased confusion

and nighttime disorders associated with psychotropic drug
use.

The current researcher also sought to identify

behaviors documented by the nursing staff before and after
the institution of psychotropic drug use in elders.
The major source of problems for physicians treating
Alzheimer's disease is controlling the psychotic types of
symptoms experienced by the persons affected. A primary
predictor of cognitive and functional decline in
Alzheimer's disease is a worsening of psychotic symptoms,
such as delusions,

hallucinations,

psychomotor function
DeKosky

aggression,

(Lopez, Wisniewski,

and

Becker,

Boiler,

&

(1999). Although the literature seems to support

the position that psychosis and abnormal behavior can
affect the progression of Alzheimer's disease,

few studies

have taken into account the medications used.
Lopez et al.

(1999)

examined whether the use of

psychiatric medication and the presence of abnormal
behaviors affects the progression of Alzheimer's disease.
A cross-sectional design was used with longitudinal
follow-up and the likelihood of arriving at one of four
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points:
lower,

(a) MiniMental State exam

(MMSE)

score of 9 or

which examines cognitive and mental status;

Blessed Dementia Rating Scale

(BDRS)

(b)

score of 15 or less,

which measures ability to perform activities of daily
living;

(c) nursing home admission;

and

(d) death.

Psychiatric medication included antidepressants,
antipsychotic agents,

and sedative/hypnotics.

The

psychotic symptoms described include such symptoms as
delusions,

hallucinations,

psychomotor agitation,

aggressive behavior,

wandering,

and depression.

The setting was the Multidisciplinary Dementia
Research Clinic in Pittsburgh,

Pennsylvania.

The subjects

consisted of 17 9 mildly to moderately impaired patients
with probable Alzheimer's disease.
from 2.4 to 172 months
months).

Patients were observed

(mean duration + SD,

49.5 + 27.4

Each patient received an extensive neurological,

psychiatric,
the study.

and neuropsychological examination prior to

Patients with clinical or radiological evidence

of cerebrovascular disease were not included in the study.
Subjects were examined annually,
period ranged from 0.2 to 14.6 years
period

+ SD,

and the follow-up
(mean follow-up

4.16 + 2.38 y e a r s ) . Psychiatric evaluations

were conducted annually by psychiatrists using a
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semistructured interview with patients and primary
ca r e g i v e r s .
The medications used by the patients were recorded on
a summary form that included dosages,
prescription,

date of the initial

and date of discontinuation of medication.

The referring physician conducted the selection,
administration,

and response evaluation of each treatment.

Student ;t tests were used to analyze demographic and
neuropsychiatrie data.

Proportional hazard models were

used to determine if there were differences in the time
from study entry to death,
scores of 15 or higher,

institutionalization,

BDRS

and MMSE scores of 9 or lower

between patients with Alzheimer's disease with and without
psychiatric symptoms and as a function of medication use
and type.

Proportional hazard models were also used to

individually assess the effect of the presence of
individual symptoms or medication-induced symptoms on
these same outcomes.

The effects of individual symptoms

and medications were assessed as time-dependent
covar i a t e s .
A step-wise selection procedure was used to determine
which psychiatric symptom or medication was independently
associated with the outcome measures,
possible confounding variables,

after adjusting for

such as sex,

age,

and
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educational background.
outcome

(e.g., death,

For patients not reaching an

institutionalization,

BDRS score of

> 15, MMSR score of < 9), data were censored using the
date of the last contact.
A total of 41 patients

(23%) were taking at least one

psychiatric medication at study entry;
antidepressants,
(6%)

16

22

(12%)

took

(9%) took antipsychotic agents,

took sedative/hypnotics.

and 11

The relationship between the

medication and the symptoms indicated that 18% of the
patients had verbal or physical aggression,
psychomotor agitation,

23% had

7% experienced wandering,

suffered from insomnia,

29%

13% had major depression,

and 26%

experienced psychotic symptoms at baseline examination.
During follow-up,

18% of the patients were noted to

be aggressive,

38.5% experienced psychomotor agitation,

19% wandering,

37% insomnia,

psychosis.

and 38%

There were more patients treated than not

treated who had aggression
agitation

9% depression,

(p < .001),

baseline examination,

(p < .001), psychomotor

and depression

(p < .001). At

17% of the 41 treated patients were

taking two or more drugs,

7% were treated with

antidepressants and antipsychotic agents,
sedative/hypnotics and antidepressants,
types of medication.

7% with

and 5% with three

During follow-up 43% took psychiatric
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medications,

12% took antidepressants,

22% antipsychotics,

and 13% sedative/hypnotics, 15% were treated with more
than one psychiatric medication,
and sedative/hypnotic agents,
antipsychotics,

3% with antidepressants

4% with antidepressants and

8% with antipsychotic and

sedative/hypnotics, 4% used more than one antipsychotic
agent,

1% used more than one antidepressant,

and 1% used

more than one sedative/hypnotic agent.
Seventy-four

(41%)

institutionalized,
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score of 15 or higher,
of 9 or lower.

of the 179 patients were
(56%) died,
and 76

(42%)

55

(31%)

reached BDRS

reached and MMSE score

Cox proportional hazard models were used to

examine the univariate effect of medication and individual
psychiatric symptoms on the outcome variables.
psychiatric medications,

Of the

antipsychotic agents were

associated with time to BDRS scores of higher than 15
= 2.02,

p = .03)

p = .02),
death

and with institutionalization

(RR

( ^ = 2.14,

sedative/hypnotics were associated with time to

(R^ = 1.96, p = .05).
Psychosis,

aggression,

and agitation were all

independently associated with time to
institutionalization. Antipsychotic agent use was
associated with BDRS scores of 15 or higher and use of
sedative/hypnotics with time to death.
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The number of patients with psychomotor agitation,
insomnia,
follow-up,

psychosis,

and wandering increased during the

while the number with depression and aggressive

behavior decreased.

Psychotic symptoms were significant

predictors of institutionalization and functional decline,
but not of death.
Lopez et al.

(1999)

determined that one of the

problems in the treatment of Alzheimer's disease is the
lack of agreement regarding who should be treated and
noted most of the patients with behavioral problems were
not being treated at study entry,

except those with

depression. As the disease progressed, more patients began
treatment,

especially those with agitation or aggression.

Of the patients with psychotic symptoms,

less than one

half received any medication.
A second implication of the Lopez et al.

(1999)

study

was the need to more closely examine what types of
psychotropic medications should be used for what types of
symptoms.

Antidepressants were not only used to treat

depression but also insomnia and episodes of nocturnal
agitation.

In the study antipsychotic agents and sedatives

were used to treat agitation,
insomnia.

wandering,

aggression,

and

This finding suggests that the choice of

treatment may be guided by the most disturbing symptom.
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The current researcher also was interested in the use of
psychotropic medications used to treat Alzheimer's disease
and the progression of the disease process.

The focus of

the current research was to identify behaviors before and
after beginning psychotropic medication therapy.
Although there were few studies available,

the review

of the literature provided valuable information regarding
Alzheimer's disease progression,
decline,

behaviors,

cognitive

and medications used to treat the symptoms.

This

study will serve to augment the limited research available
regarding the use of psychotropic medications in
Alzheimer's disease.

Summary
In this review of the literature,

the studies cited

have shown that psychotropic medications do affect
cognition and memory of Alzheimer's disease patients.
Castle

(1999)

examined nursing home size and funding

status and found that nursing homes with a high Medicaid
census used more psychotropic medications.
Dellage ga's (1996)

In Berg and

study the long-term use of

psychotropics was explored.

Berg and Dellagega determined

that elders who used psychotropic drugs had lower
cognition scores overall.

The researchers further

concluded that as the subjects aged, more psychotropic
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medications were prescribed.

McShane and Keene

(1997)

found that the use of psychotropic medications appears to
increase the rate of cognitive decline in elders.
and Winograd
physicians,

(1994)

Jacobson

found differing opinions from nurses,

and patients regarding the use of psychotropic

medications and their effects.
Numerous studies have been published regarding the
use of psychotropic medications and dementia of all types;
however,

few address the behavioral problems experienced

by the recipients of such drugs. The behaviors of the
Alzheimer's disease patient are complex in that they exist
with and without medications.

Thus,

the current researcher

determined that additional studies were needed to
determine the behaviors exhibited by the Alzheimer's
disease patient and the psychotropic medication they are
re c e i v i n g .

Chapter III
The Method
The purpose of this study was to describe behaviors
of institutionalized Alzheimer's disease patients before
and after receiving psychotropic medication therapy.
chapter addresses the design of the study,
variables,

research questions,

This

including

and limitations. Also

discussed in this chapter are setting,
sample, methods of data collection,

population and

and data analysis.

Design of the Study
The researcher chose a descriptive comparative
research design in order to identify behaviors of
Alzheimer's disease patients receiving psychotropic
medications.

The researcher used the sign in order to

describe the variables of interest without manipulating
them or implying causation for why the variables exist as
they do. The Behavioral Assessment for Institutionalized
Alzheimer's Patients Tool was adapted from the MDS 2.0
User's Manual

(MDS)

(1998)

for nursing home patient

assessment and was used to describe the behaviors of
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Alzheimer's disease patients before and after psychotropic
medications were used.

Variables
The variables of interest for this study were the
behaviors exhibited by Alzheimer's disease patients and
the psychotropic medications used to treat them as
measured by the Behavioral Assessment for
Institutionalized Alzheimer's Patients.

Intervening

variables may have included the stage of disease clients
were in when admitted to the nursing home and incongruence
in the estimation of behaviors by the nurses as documented
on the MDS

(1998)

for nursing home patient assessment.

Limitations
One limitation of the present study was the design
since the researcher lacked control of the variables and
the ability to manipulate the independent variable.
However,

utilizing this design with a chart review was

appropriate as it allowed the researcher to gain
information about Alzheimer's disease behaviors as they
were perceived by nurses in the patient's natural
environment.
The research also was limited by the complexity of
the cognitively impaired individual.

In an effort to
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offset this limitation,

the researcher adapted the

Behavioral Assessment for Institutionalized Alzheimer's
Patients from the Minimum Data Set
patients'

assessment.

(MDS)

for nursing home

The MDS is the standard assessment

tool for the institutionalized resident in the nursing
home setting.

Effort was made to operationally define the

behaviors of the Alzheimer's disease patients according to
the MDS and to specifically identify the psychotropic
medications used during the time MDS assessments were
documented.
Another noted limitation for this study was the long
term care setting,

which may not truly reflect behavioral

symptoms of all Alzheimer's disease patients receiving
psychotropic medications but was chosen for access to the
population.

External validity refers to the ability to

generalize the findings to other settings or samples
(Polit & Hungler,

1999).

Because the sample was drawn from

one nursing home in one part of the United States,
findings may not be applicable to the larger population of
institutionalized or homebound elders with Alzheimer's
disease.

Setting,

Population,

and Sample

The setting for the study was a long-term care
facility in a southeastern rural state.

The facility was
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chosen because of its geographical proximity to the
researcher.

The population included patients in the long

term care facilities with a diagnosis of Alzheimer's
disease who were receiving psychotropic medication
therapy.

In order to increase validity of the study,

one psychotropic drug was included in the study.
target sample

(N = 40)

term care facility.

only

The

consisted of patients in the long

Participants were obtained through

personal visits by the researcher to the long-term care
facility who solicited help from the MDS nurse and the
Director of Nursing.

Methods of Data Collection
Instrumen tat ion . A researcher-designed Behavioral
Assessment for Institutionalized Alzheimer's Patients

(see

Appendix A) was used to determine the behaviors exhibited
by Alzheimer's disease patients before and after receiving
psychotropic medications.
items,

This tool consisted of eight

one to identify diagnosis,

cognitive skills,
of depression,

six to measure memory,

delirium-disordered thinking,

anxiety,

behavioral symptoms,

and sad mood,

indicators

change in mood,

and a final item to identify

psychotropic medications received.

Information gathered

from each patient's chart was recorded directly on the
tool. A panel of experts assessed face validity.
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A total of 6 scores by a rating scale were obtained
from the Behavioral Assessment for Institutionalized
Alzheimer's Patients. Mean scores were used to determine
the behaviors of the subjects before and after
psychotropic medication therapy.
P r ocedure. Permission was obtained to conduct the
study from the Committee on Use of Human Subjects in
Experimentation from Mississippi University for Women

(see

Appendix B ) . Permission was also obtained from the
institution utilized in the study

(see Appendix C ) . The

MDS nurse and the Director of Nursing provided patient
charts relevant to the study, which contained diagnosis of
Alzheimer's disease and psychotropic medication use.
responsible party of each subject was contacted,

The

and

permission was granted to review each subject's chart

(see

Appendix D ) . Patient names or chart numbers were not
included on the Behavioral Assessment for
Institutionalized Alzheimer's Patients in order to assure
confidentiality.

Information was recorded on the

assessment for statistical analysis.

Method of Data Analysis
Statistical results were examined to identify the
strength of relationship between the variables.

Data were

gathered and grouped by behaviors before and after
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psychotropic medication therapy.

Results from the

Behavioral Assessment for Institutionalized Alzheimer's
Patients were analyzed using the t test. Analysis using
the t test is commonly used in situations in which a
single group yields pretreatment and post-treatment scores
(Polit & Bungler,

1999).

Summary
Chapter III described empiricalization of this
research study,

which explored the behaviors of the

Alzheimer's disease patients receiving psychotropic
medication therapy.
variables,

The design of the study,

research questions,

study were addressed.

and limitations to the

The setting,

of the study were discussed.

population,

Finally,

and sample

Methods of data collection,

including instrumentation and procedures,
discussed.

including

were also

data analysis was explained.

Chapter IV
The Findings
The purpose of this study was to identify the effects
of psychotropic medications on the behaviors of the
institutionalized Alzheimer's disease patient. A
descriptive study was implemented to describe the
behaviors exhibited by the Alzheimer's disease patient
before and after receiving psychotropic medications.
Empiricalization of the study is explained in this
chapter. A description of the participants is presented,
followed by outcomes of data analysis related to the
research question.

Description of the Sample
The sample

(N = 33) consisted of Alzheimer's disease

patients in a long-term care setting receiving
psychotropic medication therapy.

Of the participants,

26.5% were male and 73.5% were female.

Each participant

had a diagnosis of Alzheimer's disease and received at
least one psychotropic medication, with 29.4% receiving
antidepressants,

32.4% receiving antipsychotics,
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17.6%
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receiving sedative/hypnotics, and 20.6% receiving anxiolytics
The long-term care facility chosen for the study
housed 125 residents.

The sample

(N = 33) was the total

number of residents who met the criteria of diagnosis and
medication.

All of the participants had been in the

facility for at least 6 months.

Results of Data Analysis
One hypothesis guided this study.
as follows:

The hypothesis was

There will be no significant difference in the

selected behaviors of institutionalized Alzheimer's
disease patients before and after receiving psychotropic
medication therapy. A t test was used to determine the
significance of any difference in behavior for each
selected behavior on the Behavioral Assessment for
Institutionalized Alzheimer's Patients.

The selected

behaviors analyzed were memory/recall ability,

cognitive

skills,

indicators

delirium-periodic disordered thinking,

of depression,

anxiety and sad mood,

and behavioral

sy m p t o m s .
For memory there was a significant decline after
taking psychotropic medications.

The majority of the

participants went from the ability to remember four or
more items to remembering none.

The items of memory and

recall included recognition of current season,

location of
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room,

staff names and faces,

and nursing home placement.

These findings are presented in Table 1.

Table 1
Memory and Recall Behaviors of Alzheimer's Disease
Patients Using a t Test

M

Memory/Recall

SD

t

p ’^

No items recalled
Pretest

33

1.47

1. 002

Posttest

33

1.03

1. 060

2 .45

.02*

p < .05.

The cognitive skills for daily decision making ranged
from independent decision making to severely impaired
decision making.

Independent decision making indicated

that the participants made consistent and reasonable
decisions.

Modified independence indicated some difficulty

in new situations while moderately impaired decision
making required cues or supervision.

Severely impaired

decision making indicated that the participant rarely or
never made decisions.

The findings were significant in

that there was an overall increase in cognitive function
of the Alzheimer's disease patient after receiving
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psychotropic medications.

These findings are presented in

Table 2.

Table 2

Disease Patients Using a t Test

Cognitive
function

df

M

t

£*

-3.94

.000*

SD

Decision-making
level
Pretest

33

1.76

99

Posttest

33

2, 18

90

*£ <

.0 5 .

In the area of delirium-periodic disordered
thinking/awareness,

there was a significant increase in

periods of restlessness,

fidgeting,

and repetitive

physical movements of the Alzheimer's disease patients
receiving psychotropic medications.

The areas in which

there was no decline included attention span, periods of
altered perception or awareness of surroundings,
of disorganized speech, periods of lethargy,
mental function.

There was,

however,

episodes

and varying

an increase in

periods of restlessness which included fidgeting or
picking at skin,

clothing,

napkins,

etc.,

frequent
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position changes,
wandering,

pacing,

repetitive physical movements,
or calling out. These findings are

presented in Table 3.

Table 3
Indicators of Delirium and Disordered Thinking/Awareness
of Alzheimer's Disease Patients Using a t Test

Indicator

Easily distracted
Pretest
Posttest
Periods of altered
perception
Pretest
Posttest

Episodes of
disorganized
speech
Pretest
Posttest
Periods of
restlessness
Pretest
Posttest

M

SD

t

33

.471

.507

33

.500

.510

33

.320

.470

33

.470

.510

33

.260

.450

33

.350

.490

33

.260

.450

33

.500

.510

p*

-.297

.768

-1.710

.096

-1.000

.325

-2.260

.030*

(table continues)
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Table

3

(continued)

Indicator

M

SD

Periods of
lethargy
Pretest

33

.150

.440

Posttest

33

.180

.390

Mental function
varying over
the course
of the day
Pretest

33

.350

.490

33

Posttest

.500

t

p*

- .373

.711

-1.710

.096

.510

'p < .05 .

For indicators of depression,

anxiety,

or sad mood

there was a significant increase in unrealistic fears,
such as fear of being left alone,
others.

abandoned,

or being with

There was also an increase in the behavior of

repetitive questions,

such as "where do I go" and "what do

I do?" and crying and tearfulness of the Alzheimer's
disease patient receiving psychotropic medications also
escalated.

There was no increase in the behaviors of

negative statements and verbalizations such as calling
"help." There were no indic a t i o n s .of an increase in anger
with self and others,
health complaints.

self-deprecation,

or repetitive

The findings are presented in Table 4.
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Tabl e 4

Indicators of Depression, Anxiety, and Sad Mood of
Alzheimer's Disease Patients Using a t Test

Indicator

M

SD

33

-.588

.239

33

-.822

.290

33

-.294

.170

33

.150

.360

33

.120

.330

33

.260

.450

33

.120

.410

Posttest

33

.180

.390

Selfdeprecation
Pretest

33

-.294

.170

Negative
statements
Pretest
Posttest
Repetitive
questions
Pretest
Posttest
Repetitive
verbalizations
Pretest
Posttest
Persistent
anger
Pretest

Posttest

33

-.882

t

p*

-.422

.661

-2.98

.044*

-1. 96

.058

-.702

.488

-1.000

.325

.290

(table continues)
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Table 4

(continued)

Indicator

M

SD

Unrealistic
fears
Pretest

33

-.294

.170

Posttest

33

.240

.500

33

.120

.330

t

-2.500

Repetitive health
complaints
Pretest

.000
Posttest
Crying/tearfulnes s
Pretest

33

.120

.410

33

.210

.410

33

.410

.560

-2.23
Posttest

p*

.017*

1.000

.033*

*<.05.

For negative behavioral symptoms of the Alzheimer's
disease patient receiving psychotropic medications,

the

data analysis revealed that there was an increase in
physically abusive behavior,
scratching,

such as hitting,

and sexual abuse of others.

shoving,

There was no

increase in the behaviors of wandering with no rational
purpose,

verbal abuse,

residents,

and socially disruptive behavior,

disrobing in public.
5.

such as threatening other
such as

The findings are presented in Table
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Table 5

Behavioral Symptoms of Alzheimer's Disease Patients Using
a t Test

Behavior
symptom

df

Wandering
Pretest

33

M

.265

SD

.500

.860

33

.240

.430

Posttest

33

.350

.490

Physical abuse
Pretest

33

.180

.390

Posttest

33

.410

.610

33

.120

.330

33

.240

.430

Verbal abuse
Pretest

Socially
inappropriate
behavior
Pretest
Posttest

p*

.567

33

Posttest

t

-1.750

.088

-1.070

.292

-2.260

.030*

-1.430

.160

*< .05.

Since there was a significant change in areas of all
behaviors assessed.

the researcher rejected the null

hypothesis.

Summary
The results of the data analysis were described in
Chapter IV. The sample including demographics were
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included.

Each item of the Behavioral Assessment for

Institutionalized Alzheimer's Patients was statistically
analyzed to determine if any significance could be
identified.

Results from statistical analysis of

Alzheimer's disease patients' behaviors and psychotropic
medications showed a significant correlation.

The

initiation of psychotropic medications did adversely
affect the behavior of the Alzheimer's disease patient.
Chapter V will provide an outcome of the findings
including discussion,
re comm endations.

conclusions,

implications,

and

Chapter V
The Outcomes
An explanation of the findings of this study in
relation to the research problem is summarized and
discussed in this chapter.

Conclusions are drawn,

implications for nursing are examined,

and recommendations

for nursing science are made.
Psychotropic medications are frequently used to treat
the behavioral symptoms of the Alzheimer's disease
patients in the long-term care setting.

The use of

psychotropic medications in the longer-term care setting
has been presented in the literature;

however,

research

relating to psychotropic medications and institutionalized
Alzheimer's disease patients is limited.

This descriptive

study examined the use of psychotropic medications on the
behaviors of institutionalized Alzheimer's disease
patients.

Data were collected using the researcher-adapted

Behavioral Assessment for Institutionalized Alzheimer's
Patients.

Johnson's Behavioral Systems Model provided the

theoretical framework.
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S u m m a r y of Findings

A total of 33 Alzheimer's disease patients were
studied with 26.5% male and 73.5% female.

Psychotropic

medications identified were antidepressants,
antipsychotics,

sedative/hypnotics,

and anxiolytics.

The

null hypothesis that guided this study was as follows:
There will be no significant difference in the behaviors
of institutionalized Alzheimer's disease patients before
and after receiving psychotropic medication therapy.

The

six categories measured were memory/recall ability,
cognitive skills for daily decision making,

indicators of

delirium-periodic disordered thinking/awareness,
indicators of depression,
mood,

anxiety,

and behavioral symptoms.

sad mood,

change in

The findings revealed a

significant change in each of the six categories;
therefore,

the null hypothesis was rejected.

Discussion
Findings revealed that the memory/recall ability of
the Alzheimer's disease patient declined after the
introduction of psychotropic medications.

The Behavioral

Assessment for Institutionalized Alzheimer's Patients
measured the number of items remembered.
location of room,

staff names or faces,

Current season,
and awareness of

being in a nursing home were the elements of the
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memory/recall ability section.

The study sought to reveal

how many of these items were remembered or if none were
remembered.

The memory loss exhibited by the Alzheimer's

disease patients receiving psychotropic medications could
have been due to side effects from the drugs,
apathy,

anxiety,

drowsiness,

such as

or confusion. Although the

normal progression of Alzheimer's disease is a gradual
worsening in memory,

psychotropic drugs may potentiate

memory loss due to the fact that the elderly do not
metabolize drugs as effectively as younger people.
The cognitive skills for daily decision-making
ability increased in the patients.

The Behavioral

Assessment for Institutionalized Alzheimer's Patients
measured decisions regarding the tasks of daily life.
Specific findings included the following:
1. Modified independence was identified as some
difficulty in new situations only.
2. Moderate cognitive impairment required cues or
supervision for adequate decision making.
3. Severe cognitive impairment was indicated by
decisions being rarely or never made.
The finding of an increase in cognitive decision
making in the light of worsening memory was surprising.
This finding may be explained by the fact that although
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the memory may be worsened for the Alzheimer's disease
patient with the use of psychotropic drugs there may be an
increase in concentration.

Even though the patient may not

be aware of the season or nursing home placement,

clothing

may be selected or food likes or dislikes may be favored,
i.e.,

when asked,

"Which pair of pants do you want to

wear?" the patient may choose one. This would indicate an
increase in cognition.
Berg and Dellagega
(1997)

(1996)

and McShane and Keene

seem to contradict the current research in the area

of cognition.

Berg and Dellagega explored factors that

affected cognitive function of elders including
psychotropic medications.

The results of the study

revealed that elders who used psychotropic medications had
significantly lower cognitive scores than elders who did
not use psychotropic medications.

McShane and Keene found

that demented patients receiving psychotropic medications
had more cognition problems than those who were not
receiving such drugs.
aggression,

Findings revealed that physical

hallucinations,

present in these patients.

and persecutory ideas were
The findings of the current

research indicate an increase in cognitive function after
receiving psychotropic medications.
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The indicators of delirium-periodic disordered
thinking/awareness measured whether or not the behavior
was present and appeared different from the residents'
usual functioning.

The following items are examples of the

indicators that were measured:
1. Easily distracted indicated difficulty paying
attention or easily sidetracked.
2. Periods of altered perception or awareness of
surroundings as demonstrated by moving l ip s, talking to
someone who is not present,
somewhere else,

belief that the patient is

and confusion between night and day.

3. Episodes of disorganized speech were determined by
fidgeting or picking at skin or clothing,
position changes,
wandering,

frequent

repetitive physical movements,

pacing,

or calling out.

4. Sluggishness,

staring,

difficult to arouse,

and

little body movements indicated periods of lethargy.
5. The changes in mental function of the Alzheimer's
disease patient,
day goes on,

such as deterioration in memory as the

indicated mental function varying over the

course of the day.
The findings revealed that the episodes of deliriumperiodic thinking/awareness were increased as indicated by
an increase in periods of restlessness.

The periods of
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restlessness may be explained by the fact that the
increased cognition may have triggered restlessness in the
patient receiving psychotropic medications because the
patient may have been more cognizant to some facts as
previously descr i b e d . The increased restlessness may have
also been psychotropic drug-induced anxiety.

This finding

is consistent with the findings of Lopez et al.

(1999)

which indicated that psychotropic medications cause an
increase in psychomotor movements.
The episodes of depression,

anxiety,

and sad mood

were measured from not occurring to occurring within the
last 30 days or occurring 6 to 7 times a week.
behaviors that indicated depression,

anxiety,

The
and sad mood

were as follows:
1. Statement such as "nothing matters," "would rather
be dead," and "what's the use?"
2. Repetitive questions,

such as "Where do I go?" and

"What do I do?"
3. Calling out for help or other repetitive
ve r balizations.
4. Persistent anger with self or others from nursing
home placement to anger at care received.
5. Self-deprecation statements of unworthiness.
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6. Expression of what appears to be unrealistic
fears,

fears of being abandoned,

left alone,

or of being

with o t h e r s .
7. Repetitive health complaints and obsessive concern
with body functions.
8. Crying and tearfulness.
The findings indicate an increase in the area of
unrealistic fear.
abandoned,
Again,

These fears included fear of being

left alone,

and also fear of being with others.

this may also be correlated to the increase in

cognition because of an interest in awareness and thought
but at the same time decrease in memory may provoke
feelings of fear.

The fear of being with others,

health care professionals,

such as

may ignite fears of the unknown

(i.e., procedures and medications)
possibility of painful stimuli.

and the relation of the

The fear of being with

others may also include family members.
experience feeling of guilt,

shame,

The patient may

or frustration which

may appear as fear during times of family confrontation.
The last item measured was behavioral symptoms which
included wandering,

verbal abuse, physical abuse to staff

or other residents,

and socially inappropriate behavior

such as disrobing in public. A range of the behavior not
occurring in the last 7 days to the behavior occurring
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daily were used to measure these areas.

The findings

revealed an increase in physical abuse,

such as hitting

and scratching of staff members,
family.

other residents,

or

This also included sexual abuse of staff members,

such as inappropriate touching.

The increase in physical

abuse may be correlated to the increase in unrealistic
fears.

Fear can provoke many reactions,

and many times

Alzheimer's disease patients respond physically due to
their inability to adequately communicate,

which can be

interpreted as abuse from the caregiver or family member.
Findings from the current study imply that the
variable of psychotropic medications do adversely affect
the behaviors of the Alzheimer's disease patient.

This

finding may be compared with previous research conducted
by Lopez et al.

(1999) . The study examined the use of

psychotropic medications and the progression of behaviors
of the Alzheimer's disease patient and indicated that
behaviors,

such as verbal abuse, physical aggression,

wandering,

increased with psychotropic medication use.

and

Results of the current study supplement these findings
with a significant relationship between behaviors of the
Alzheimer's disease patient and psychotropic medication.
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Conclusions
Several conclusions can be derived from the findings
in this study.

This researcher concluded that psychotropic

medications significantly impact behaviors of the
Alzheimer's disease patient.

Many of the side effects of

psychotropic medications mimic the symptoms exhibited by
the Alzheimer's disease patient.

It is very difficult to

distinguish between the drug effects and the natural
course of the disease process;

therefore,

it is the hope

of the current researcher that the study will stimulate
more research in Alzheimer's disease and the current
treatments being used to control adverse b e h a v i o r s .
Although the current researcher believes that
psychotropic medications increased the negative behaviors
of the Alzheimer's disease patient,

the fact that the

normal progression of Alzheimer's disease also may
increase negative behavior and cannot be ignored. As the
Alzheimer's disease patient progresses through the course
of the disease,

they exhibit many disturbing behaviors.

These behaviors include wandering,
abuse.

agitation,

and physical

These are the main reasons Alzheimer's disease

patients are placed on psychotropic medications. Although
the findings did not reveal an increase in wandering,

they

did indicate an increase in physical abuse and agitated
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type behaviors.

The current researcher found the adverse

effects outweighed the benefits of psychotropic
medications in the use of Alzheimer's disease for the
patients in this study.

Implications for Nursing
A number of implications for nursing science were
derived from this study.
research,

theory,

Implications are suggested for

practice,

and education.

Re s e a r c h . Limited studies were found that examined
psychiatric drug therapy and institutionalized Alzheimer's
disease patients.

Therefore,

more research is needed to

determine the effects of psychotropic drug therapy on
Alzheimer's disease. Additionally,

research should

investigate Alzheimer's disease behaviors and the use of
medications to control them. The findings from such
research could impact the care of Alzheimer's disease
patients in long-term care facilities.
T h e o r y . This study effectively utilized Johnson's
Behavioral Systems Model as a theoretical framework.

The

concepts of maintenance and balance of functioning through
the behavioral system,
were validated.

equilibrium,

tension,

and stressors

The concepts of Johnson's model can be

readily applied to the care of the Alzheimer's disease
patient as the Alzheimer's disease patient is constantly
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Striving to maintain equilibrium and balance within the
system.

This study adds to the data base of research on

Alzheimer's disease patients utilizing a systems model as
a framework.
Pract i c e . In providing care to elders,

nurse

practitioners must be aware of the impact of Alzheimer's
disease and the medications used to treat behaviors.

The

nurse practitioner could use the results of this study to
enhance supportive care of the Alzheimer's disease
patient.

In addition,

being aware of the negative effects

of psychotropic medications might assist caregivers in
anticipation of negative behaviors and risks in these
patients such as unwanted falls and injuries.
E d u c a t i o n . This research study contributed to the
existing body of nursing knowledge regarding the effects
of psychotropic medications on Alzheimer's disease
patients. As the elder population increases,

it is

essential that nurse practitioners be prepared to respond
to the special needs of the Alzheimer's disease patient.
The findings of this study indicate Alzheimer's disease
patients receiving psychotropic medications exhibited an
increase in negative behaviors.

Education of nursing

students should include information regarding the special
needs of Alzheimer's disease patients.

The health care
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risks for these patients can be prevented if awareness of
the detrimental effects of drug therapy is anticipated.

Recommendations
Based on the findings of this study,

the following

recommendations are made :
1. Replication of a similar study with a larger
sample to evaluate the effects of psychotropic medications
on institutionalized Alzheimer's disease patients'
behaviors.
2. Refinement of the Behavioral Assessment for
Institutionalized Alzheimer's Patients to more fully
measure the behaviors exhibited.
3. Education of personnel at all levels regarding the
behaviors of the Alzheimer's disease patient and
psychotropic medications used to treat them.
4. Comparison of the effects of different
psychotropic medications on the behaviors of Alzheimer's
disease patients.

R EF ER EN CES

67

References

AstraZeneca. (2000) . Physicians ' desk reference
e d .). Montvale^ N J : Medical Economics.

(54'^’^

B e r g y S., & Dellagega, C. (1996) . The use of
psychoactive medications and cognitive function in older
adults. Journal of Aging and Health. 8 (1). 13 6-149.
Callaway, J. T. (1998). Psychopharmacological
treatment of dementia. Research on Social Work Practice.
8(4), 452-474 .
Castle, N. A. (1999). Changes in resident and
facility risk factors for psychotropic drug use in nursing
homes since the Nursing Home Reform Act. Journal of
Applied Gerontology. 18. 77-98.
Corcoran, M. A . , & Gitlin, L. N. (1992). Dementia
management: An occupational therapy home-based
intervention for caregivers. American Journal of
Occupational Therapy, 4 6 (9),801-808.
Fuller, G. F . (2000). Falls in the elderly. American
Family Physician. 6 1 (7). 2159-2172.
Gambert, S. R. (1997). Is it Alzheimer's disease?
Primary care physicians' growing responsibility for
diagnosis. Postgraduate Medicine. 1 0 1 (6) . 42-56.
Gardner, M. E ., & Garrett, R. W. (1997). Review of
drug therapy for aggressive behaviors associated with
dementia. Nursing Home Medicine. 5 (6). 199-207.
Jacobson, D. H . , & Winograd, C. H. (1994).
Psychoactive medications in the long-term care setting :
Differing perspectives among physician, nursing staff, and
patients. Journal of Geriatric Psychiatry and Neurology.
7. 176-183.
Johnson, D. E. (1968) . Theory in nursing : Borrowed
and unique. Nursing Research. 17 (3) . 2 06-2 09.

68

69

Lopez, O. L ., Wisniewski, S. R . , Becker, J. T.,
Boiler, F ., & DeKosky, S. T. (1999). Psychiatric
medication and abnormal behavior as predictors of
progression in probable Alzheimer's disease. Archives of
Neurology. 5 6 (10). 1266-1272.
M e S h a n e , R . , & Keene, J. (1997). Do neuroleptic drugs
hasten cognitive decline in dementia? Prospective study
with necropsy follow-up. British Medical Journal. 314.
266-279.
MDS 2.0 u s e r 's m a n u a l . (1998, J a n u a r y ) . Des Moines,
10: Briggs Corp. (Stock #7663).
Polit, D ., & Hungler, B. (1999) . Nursing research:
Principles and methods (6^^ ed.) . Philadelphia : L i p p i n c o t t .
Sherman, D. S. (1994). Geriatric
psychopharmacotherapy: Issues and concerns. Generations :
Journal of the Western Gerontological Society, 18(2), 3439.
Sloan, P. D. (1998). Advances in the treatment of
Alzheimer's disease. American Family Physician, 5 8 (7),
1577-1586.
Tariot, P. N., Schneider, L ., & Porsteinson, A. P.
(1997). Treating Alzheimer's disease pharmacologic options
now and in the near future. Postgraduate Medicine, 1 0 1 (6),
73-90.
Thomas, C. L. (1993) . Taber's cyclopedic medical
dictionary (17^*^ ed. ) . Philadelphia, PA: F. A. Davis.
Wechsler, D. (1972). Measurement and appraisal of
adult intelligence. Baltimore, MD: Williams and W i l l i a m s .
Yeager, B. F . , Farnett, L. E ., & Ruzicka, S. A.
(1995). Management of behavioral manifestations of
dementia. Archives of Internal Medicine, 155, 250-260.

APPENDIX A

BEHAVIORAL ASSESSMENT FOR INSTITUTIONALIZED
ALZHEIMER'S PATIENTS

70

71

Behavioral Assessment for Institutionalized
Alzheimer's Patients
1. Diagnoses

2. Memory/recall ability
{code for m e m o r y / r e c a l l )
______ 0. Current season
______ 1. Location of room
______ 2. Staff names/faces
______ 3. That he/she is in a nursing home
______ 4. None of the above are recalled
5. Two or more of the above are recalled

3. Cognitive Skills for daily decision-making
(made decisions regarding tasks of daily life)
_____
_____
_____
_____

0. Independent--decisions consistent and reasonable
1. Modified independence— some difficulty in new situations only
2. Moderately impaired— decisions poor: cues/supervision required
3. Severely impaired— never/rarely made decisions

4. Indicators of delirium--periodic disordered
thinking/awareness
_

(Code for behavior occurring in the last 7 days)
0. Behavior not present
______ 1. Behavior present
______ 2. Behavior present--appears different from resident's
usual functioning
______
______

______

______

______
______

a. Easily distracted (difficulty paying attention: gets
sidetracked)
b. Periods of altered perception or awareness of surroundings
(moves lips or talks to someone who is not present/believes he
is somewhere else : confuses night and day)
c. Episodes of disorganized speech (incoherent, nonsensical,
irrelevant, or rambling from subject to subject; loses train of
thought)
d. Periods of restlessness (fidgeting or picking at skin, clothing,
napkins, etc..; frequent position changes; repetitive physical
movements, wandering, pacing, or calling out)
e. Periods of lethargy (sluggishness, staring into space, difficult
to arouse, little body movement)
f. Mental function varies over the course of the day (sometimes
better, sometimes worse, behaviors sometimes present, sometimes
not)
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5. Indicators of depression, anxiety, sad mood
(Code for indicators observed in the last 30 days)
_____ 0. Indicator not exhibited in the last 30 days
_____ 1. Indicator of this type exhibited up to 5 days/week
_____ 2. Indicator of this type exhibited daily or almost daily
6-7 days/week
______ a. Resident makes negative statements (Nothing matters. W ould
rather be dead. What's the use)
______ b. Repetitive questions ("Where do I go. What do I do?")
______ c. Repetitive verbalizations (calling out for help)
______ d. Persistent anger with self or others (easily annoyed, anger at
placement in nursing home, anger at care received)
______ e. Self-deprecation ("I am nothing; I am of no use to anyone")
______ f. Expression of what appears to be unrealistic fears (fear of
being abandoned, left alone, being with others)
______ g. Repetitive health complaints (seeks medical attention, obsessive
concern with body functions)
______ h. Crying, tearfulness

Change in mood
(Resident's mo o d status has changed as compared to status of 90 days ago)
_____
_____

0. No change
1. Improved
2. Deteriorated

Behavioral symptoms
(Behavioral symptom frequency in last 7 days)
______ 0. Behavior not exhibited in last 7 days
______ 1. Behavior
of
this
type occurred 1to 3days in last
7
days
______ 2. Behavior
of
this
type occurred 4to 6days, but less
than daily
______ 3. Behavior
of
this
type occurred daily
_____
_____
_____
_____

a. Wandering (moved with no rational purpose, seemingly oblivious
to needs or safety)
b. Verbally abusive behavioral symptoms (others were threatened,
screamed at, cursed at)
c. Physically abusive behavioral symptoms (others were hit, shoved,
scratched, sexually abused)
d. Socially inappropriate/disruptive behavioral symptoms (made
disruptive sounds, noisiness, screaming, self-abusive acts,
sexual behavior, or disrobing in public)

Medications
(List all psychotropic medications the patient is currently on.
scheduled psychotropics and PRN psychotropics)

Medication Name

Dose Ordered

Route

A d a pted from the M i nium Data Set for nursing home residents

Included

Frequency
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May 12, 2000

Mary Beth McKinney
229 County Road 152
Corinty, M s 38834

Dear Mary Beth,
I am happy to inform you that w e will be glad to have you conduct your study at out facility
Please be aware o f patient confidentiality issues. W e will be interested in the findings o f your
study.

Sincerely,

Richard Atkins, Adm

APPENDIX D

LETTER REQUESTING PERMISSION TO
CONDUCT STUDY
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229 County Road 152
Corinth, MS 38834
(662) 287-8383

Alcorn County Care Inn
Joanne Drive
Corinth, MS 38834
ATTENTION:

Richard Atkins

Dear Mr. Atkins:
As a graduate student at Mississippi University for Women,
I will be conducting a research study. In the course of my
experience in geriatrics, I have become aware of the
number of people affected by Alzheimer's disease. In my
proposed research study, I plan to study Alzheimer's
patients and the behaviors they exhibit. I would like to
conduct my research at your facility through a chart
review. There will be no actual patient contact during
this study. This study is strictly confidential and in no
way would the facility name or resident name be used. I
will use a numbering system for identification. As the
guardian of the residents I am asking your permission to
conduct my research study in your facility.
Please share this with others in administration and let me
know if it meets with your approval. If there are any
questions regarding this study, please feel free to
contact me. Thanks for your time in reviewing this.
Sincerely,

Mary Beth McKinney,

RN, C, BSN

